Summarized by Masters of Longevity from PR Newswire.
Phase 2 VENTURE found 74% improved by at least one BMI category.
Key Takeaways
- VK2735 treatment was associated with greater cardiometabolic improvements.
- 74% of VK2735 patients improved by at least one BMI category.
- Findings are from a 13-week Phase 2 trial and are exploratory.
